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TO THE EDITOR
Primary cutaneous CD30-positive lym-
phoproliferative disorders are the
second most common group of pri-
mary cutaneous T-cell lymphomas
(Willemze et al., 2005), after the
mycosis fungoides/Se´zary syndrome
group. The clinical and histological
features of primary cutaneous anaplas-
tic large-cell lymphoma (C-ALCL) have
been well characterized, but little is
known about its underlying patho-
genetic and genetic alterations. Pre-
vious comparative genomic hybridiza-
tion (CGH) studies focusing on C-ALCL
that included a limited number of
samples yielded nonhomogeneous
results (Bo¨ni et al., 2000; Mao et al.,
2003; Prochazkova et al., 2003; Fischer
et al., 2004; Zettl et al., 2004).
Recently, three studies that were based
on array CGH (aCGH) and included a
small number of C-ALCL patients were
published (Mao et al., 2003; Laharanne
et al., 2010; van Kester et al., 2010).
We have investigated the genomic
profile of 19 C-ALCL patients using a
60-mer 44K oligonucleotide-array-
CGH platform and compared our
results with those of previous aCGH
studies. C-ALCL patients were selec-
ted according to the World Health
Organization–European Organization
for Research and Treatment for
Cancer (EORTC) classification for cuta-
neous lymphomas (Willemze et al.,
2005). This EORTC multicenter study
was conducted in the departments
of pathology and dermatology of
six European centers in Spain and
Switzerland. The local ethics commit-
tees approved the study, and written
informed consent was obtained from all
patients, in accordance the Declaration
of Helsinki Principles. Clinical charac-
teristics are detailed in Supplementary
Table S1 online. The study was
performed with 2010 mm snap-frozen
C-ALCL samples to ensure the high
quality of the DNA. Hematoxylin–eosin
staining of a frozen section of
each sample was performed tumor cell
infiltration of at least 70%. DNA
was isolated using a commercial kit as
described in manufacturer’s instruc-
tions (Dneasy Blood and Tissue Kit;
Qiagen, Hilden, Germany). Genome-
wide analysis of patient samples
was conducted using the Human Gen-
ome CGH 44K microarrays (G4410B
and G4426B; Agilent Technologies,
Palo Alto, CA), a whole-genome plat-
form containing 44,000 probes along
the entire human genome with a mean
resolution of ±75 kb. Hybridization
was performed according to the manu-
facturer’s protocols. Data analysis
was conducted as previously described
(Salgado et al., 2010). Fluorescence
in situ hybridization with noncom-
mercial probes of bacterial artificial
chromosome DNA clones from the
CHORI bacterial artificial chromo-
some/PAC resource (http://bacpac.
chori.org) was performed to confirm
chromosomal abnormalities previously
detected by aCGH in cases for which a
paraffin-embedded tissue biopsy was
available.
Chromosomal abnormalities were
detected in 17 of 19 analyzed C-ALCL
samples (89.5%). Losses were more
frequently detected than gains (78.9
vs. 68.4%). Mao et al. (2003) and
van Kester et al. (2010) found gains
more frequently than losses, whereas
Laharanne et al. (2010) detected losses
more frequently. The highest frequen-
cies of chromosomal aberrations
were 60% (Mao et al., 2003) and 45%
(Laharanne et al., 2010; van Kester
et al., 2010), in contrast to 36.8%
in our present study. Regarding
the smallest overlapping regions of
imbalance, 15 corresponded to losses
and 9 to gains. The results are summar-
ized in Figure 1 and detailed in
Supplementary Table S2 online. The
specific chromosomal regions and can-
didate genes mapped in these regions
are detailed in Table 1. The most
frequent abnormalities observed were
deletions located on 16q, 13q, 17p13,
and 20q13. Genomic losses of 13q34
(ING1) and 16q22.11 (CTCF) detected
by aCGH were confirmed by fluores-
cence in situ hybridization in three
patients. No significant correlation be-
tween the observed clinical features
and the presence of chromosomal
aberrations could be demonstrated.
Furthermore, no data regarding the
prognostic significance of the observed
genetic results were obtained.
In agreement with studies by van
Kester et al. (2010) and Laharanne et al.
(2010), two regions were lost in our
study, at 13q33.3 and 16p11.2. These
regions were not detected in the first
aCGH study (Mao et al., 2003), prob-
ably because they may not have been
among the 57 oncogenic regions of
the AmpliOnc platform. Similar to the
findings of van Kester et al. (2010), we
observed losses at 3p26.3, 6q21, 8p22,
13q12.11, 13q13.1, 16p11.2-16q11.2,
17p13.1, and 17p13.3 (Supplementary
Table S3 online). The main concor-
dance between our results and those of
van Kester et al. (2010) was a dele-
tion at 16q11.2. However, differences
were observed for a higher frequency
of 16q losses in our series, including
seven genomic regions located be-
tween 16q11.2 and 16q24.3. The most
Abbreviations: aCGH, array comparative genomic hybridization; C-ALCL, primary cutaneous anaplastic
large-cell lymphoma; CGH, comparative genomic hybridization
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Figure 1. Oligonucleotide array comparative genomic hybridization results. The red lines on the right represent gains of genomic DNA; the green lines on the
left represent losses.
Table 1. Minimal common regions altered in C-ALCL patients
Chromosome
region Start End
Size
(Mb)
No. of
oligos
% of
patients
No. of
patients Candidate genes
Gains
16p13.3pter 36,766 3,010,789 2,974,023 158 21 4 No candidate oncogenes
1p36.32pter 604,268 3,365,901 2,761,633 55 15.8 3 MIB2, SKI, PRDM16
1p36.31 6,873,413 14,048,567 7,175,154 131 15.8 3 PARK7, DFFA, PRDM2
Losses
16q12.1 46,054,090 61,107,792 15,053,702 272 36.8 7 SIAH1,SALL1,RBL2, FTS, BBS2,
MT4, CX3CL1, GPR56, NDRG4
16q22.1 65,554,899 66,583,837 1,028,938 73 36.8 7 CBFB, TRADD, E2F4, CTCF, THAP11
16q24.3 87,305,787 88,086,690 780,903 27 36.8 7 CBFA2T3, ANKRD11
16q11.2 45,172,598 46,050,598 878,000 25 31.6 6 IRX5
16q21 61,200,747 65,530,238 4,329,491 62 31.6 6 CDH5, CDH11, CDH16
16q22.1 66,612,927 87,294,503 20,681,576 455 31.6 6 NFATC3, CDH1, DERPC, NQ01,
ZNF23, CHST4, ATBF1, ADAMTS18,
WWOX, DNCL2B, CDH13, HSBP1,
OKL38, WFDC1, FBX031,
BANP, IL17C
16q24.3 88,117,217 88,651,780 534,563 41 31.6 6 DPEP1, ZFP276, GAS8
13q33.3 105,942,094 114,077,122 8,135,028 106 26.3 5 LIG4, COL4A1, ING1, SOX1, LAMP1
13q14.3 52,209,360 55,484,740 3,275,380 17 21 4 No candidate tumor supressor genes
13q21.32 57,692,811 105,913,242 48,220,431 404 21 4 DIAPH3, PCDH20, PCDH9, DACH1,
SCEL, EDNRB, POU4F1, SPRY2,
DNAJC3, ZIC2, ERCC5
16p13.13 11,243,506 11,745,706 502,200 15 21 4 LITAF
16p13.12 14,453,435 16,213,237 1,759,802 44 21 4 NDE1
17p13.1 7,187,732 7,537,896 350,164 35 21 4 TNK1, CHRNB1, ZBTB4, POLR2A,
SAT2, TP53, FLJ10385
20q13.13 47,987,034 49,388,214 1,401,180 26 21 4 CEBPB
Abbreviation: C-ALCL, primary cutaneous anaplastic large-cell lymphoma.
Losses on chromosome 19 were not considered in the final analysis owing to the difficulties of evaluating chromosomal copy number imbalances.
270 Journal of Investigative Dermatology (2011), Volume 131
JMa Sa´nchez-Schmidt et al.
Genetic Characterization of C-ALCL-CD30þ by ACGH
remarkable difference was the higher
frequency of 7q gains reported by van
Kester et al. (2010). These discrepancies
could be due to the small number of
C-ALCL cases analyzed heretofore.
The most interesting regions of loss
were those affecting CTCF (16q22.1),
ANKRD11 (16q24.3), ING1 (13q33.3),
and TP53 (17p13.1), all of which are
involved in the TP53 signaling path-
way. Interestingly, 17p13.1 deletion
was observed in four patients. Two of
them presented recurrences and/or lymph
node involvement. In one of these
patients, we could confirm the TP53
deletion by fluorescence in situ hybridi-
zation, and we also detected a TP53
mutation both in the diagnostic sample
and in the recurrence lesion (data not
shown). Moreover, 10 of 19 (53%)
patients displayed one or more defects
affecting this pathway, which we consider
important in the pathogenesis of C-ALCL.
In conclusion, taking into account
the results of these aCGH studies, we
conclude that chromosomal imbal-
ances detected in C-ALCL are hetero-
geneous and that no characteristic
pattern of chromosomal aberrations
has yet been identified.
Although a high percentage of
C-ALCL patients showed genetic ab-
normalities, most of them presented a
small number of alterations (median 4,
range 0–16), and these were highly
heterogeneous between patients and
without a clear recurrent pattern, unlike
other cutaneous T-cell lymphomas.
Differences in sample selection criteria
and technical approaches among
studies (Mao et al., 2003; Laharanne
et al., 2010; van Kester et al., 2010; our
present study) may explain in part these
inconsistent results. In addition, the
possibility that C-ALCL represents a
heterogeneous group of disorders from
the genetic point of view cannot be
completely ruled out. Moreover, other
altered genetic mechanisms—such as
gene mutations, methylation, aberrant
miRNA expression, or the presence of
acquired uniparental disomy—that do
not implicate gains or losses of DNA
could be involved in the pathogenesis
of C-ALCL. Therefore, exploration of
such genome and transcriptome mod-
ifications in larger series of patients is
necessary in order to understand the
biology of this tumor.
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